12:00 AM
 | 
Feb 11, 2013
 |  BioCentury  |  Emerging Company Profile

EnBiotix: Enhancing antibiotics

EnBiotix using two mechanisms to increase sensitivity to antibiotics

EnBiotix Inc. is discovering compounds that make infections more susceptible to existing antibiotics either by increasing the bacterias' production of reactive oxygen species, or by activating their metabolic pathways. The company is aiming for a discovery alliance followed by an A round that will help fund development of its candidates.

EnBiotix's discovery programs are based on the work of Boston University's James Collins, whose lab has used systems biology approaches to study bacterial responses to antibiotics. Collins is a professor of biomedical engineering at the university, a founding core member of the Wyss Institute for Biologically Inspired Engineering at Harvard University and a Howard Hughes Medical Institute investigator.

Work from his lab published in 2007 in Cell showed that bactericidal antibiotics with different targets, including beta lactams, quinolones and aminoglycosides, all kill bacterial cells through a common downstream mechanism - the production of lethal amounts of reactive oxygen species (ROS).

Last month in Nature Biotechnology, Collins described an in silico and in vitro screening...

Read the full 820 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >